Transcript Human Genome II - Open.Michigan

Author(s): David Ginsburg, M.D., 2012
License: Unless otherwise noted, this material is made available under the terms of
the Creative Commons Attribution–Non-commercial–Share Alike 3.0 License:
http://creativecommons.org/licenses/by-nc-sa/3.0/
We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your
ability to use, share, and adapt it. The citation key on the following slide provides information about how you
may share and adapt this material.
Copyright holders of content included in this material should contact [email protected] with any
questions, corrections, or clarification regarding the use of content.
For more information about how to cite these materials visit http://open.umich.edu/education/about/terms-of-use.
Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis
or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please
speak to your physician if you have questions about your medical condition.
Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.
Attribution Key
for more information see: http://open.umich.edu/wiki/AttributionPolicy
Use + Share + Adapt
{ Content the copyright holder, author, or law permits you to use, share and adapt. }
Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105)
Public Domain – Expired: Works that are no longer protected due to an expired copyright term.
Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain.
Creative Commons – Zero Waiver
Creative Commons – Attribution License
Creative Commons – Attribution Share Alike License
Creative Commons – Attribution Noncommercial License
Creative Commons – Attribution Noncommercial Share Alike License
GNU – Free Documentation License
Make Your Own Assessment
{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }
Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in
your jurisdiction may differ
{ Content Open.Michigan has used under a Fair Use determination. }
Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your
jurisdiction may differ
Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that
your use of the content is Fair.
To use this content you should do your own independent analysis to determine whether or not your use will be Fair.
The Human Genome II
M1 Patients and Populations
David Ginsburg, MD
Fall 2012
Relationships with Industry
UMMS faculty often interact with pharmaceutical, device, and
biotechnology companies to improve patient care, and develop
new therapies. UMMS faculty disclose these relationships in
order to promote an ethical & transparent culture in research,
clinical care, and teaching.
•I am a member of the Board of Directors for Shire plc.
•I am a member of the Scientific Advisory Boards for Portola
Pharmaceuticals and Catalyst Biosciences.
•I benefit from license/patent royalty payments to Boston
Children’s Hospital (VWF) and the University of Michigan
(ADAMTS13).
Disclosure required by the UMMS Policy on Faculty Disclosure of Industry Relationships to Students and Trainees.
Learning Objectives
UNDERSTAND:
• The basic anatomy of the human genome [eg. 3 X109 bp (haploid
genome); 1-2% coding sequence (~20,000 genes); types and extent of
DNA sequence variation].
• Recombination and how it allows genes to be mapped
• Genetic data for a pedigree, assigning phase, defining haplotypes
• Linkage: Distinction between a linked marker and the disease causing
mutation itself
• Linkage disequilibrium and haplotype blocks
• Genome wide association studies (GWAS) to identify gene variants
contributing to complex diseases/traits
• The implications of GWAS findings for clinical care and “Personalized
Medicine”
• The implications of “Next-Gen” sequencing for future clinical medicine
genetics/genomics in the clinic
• Better/earlier diagnosis:
– Mendellian disorders
– Complex disorders
Exceeding
expectations
• Guiding/selecting treatment:
– Subclassifying cancers
• Somatic mutations
• Expression profiles
FAR below
expectations
/promises
– Customized/designer treatment
– Pharmacogenomics
Positional Cloning
FAMILIES
FINE
GENETIC
MAPPING
PHYSICAL
MAPPING
AND
CLONING
TRANSCRIPT
IDENTIFICATION
GENETIC
MARKERS
MUTATION
SEARCH
MUTATION
IDENTIFICATION
YACs and
BACs
POSITIONAL
CANDIDATE
APPROACH
Gelehrter, Collins and Ginsburg: Principles of Medical Genetics 2E; Figure 9.15
http://www.ncbi.nlm.nih.gov/Omim/mimstats.html
Complex Diseases
•
•
•
•
•
•
Hypertension
Coronary artery disease
Diabetes
Obesity
Cancer
…
Difficult to map in large pedigrees by conventional
linkage (multiple genes, variable effects)
• Candidate gene association study
– Test a SNP (or SNPs) surrounding your
favorite gene for association with disease
(more common in patients than controls)
• Publication bias
• Multiple observations
• Population substructure
• “looking under the streetlamp”
vs.
• Genome-wide association study (GWAS)
– Unbiased
– No prior assumptions
Human Chromosome 4
1981
1991
1994
1996
2010
• 23,653,737 total
human entries in
dbSNP
http://www.ncbi.nlm.nih.
gov/projects/SNP/
• Chromosome 4
– 4,311,728 SNPs
• ~1M SNP chip
commercially
available
3 markers
53 markers
393 markers
791 markers
Gelehrter, Collins and Ginsburg: Principles of Medical Genetics 2E; Figure 10.3
Science, April 15, 2005
•
Age-related macular degeneration (AMD)
– > 10 million cases in the US
– Leading cause of blindness among the elderly
•
Common variant in complement factor H (CFH) gene
– Tyr402His
– His allele = 2-4 X increase risk of AMD
– Accounts for 20-50% of AMD risk
All clippings
All clippings
The Multiple observations problem
• Roll the dice once
– Probability of rolling two 6’s = 2.8% (1:36=1/6 X 1/6)
• Roll the dice twice
– Probability of rolling two 6’s at least once = 5.5%
• Roll the dice 100 times
– Probability of rolling two 6’s at least once = 94%
Test 1 million SNPs, 100 phenotypes . . .
Type 2 Diabetes GWAS: Manhattan Plot
Voight et al., Nature Genetics, 42:579, 2010.
Lyssenko et al. Clinical risk factors, DNA
variants, and the development of type 2 diabetes.
N Engl J Med. 359:2220, 2008.
Conclusions:
“As compared with clinical risk factors alone,
common genetic variants associated
with the risk of diabetes had a small effect on
the ability to predict the future development
of type 2 diabetes.”
Diabetes Risk
• Obesity OR=>3
• Family history OR=>3
• GWAS SNPs OR=<<1.4
+
>>
Ricardipus (wikipedia)
Other Genome Wide Association Studies
(GWAS)
• Heart disease
– MI, AF, QT prolongation, CAD, lipids
• Inflammatory bowel disease
• Asthma
• Neuropsychiatric disorders
– ALS, MS, Alzheimer, schizophrenia, bipolar disorder
• Rheumatologic disorders
– RA, SLE
• Cancer risk
– breast, prostate, colon
• Common traits
– BMA, height, hair/eye/skin color
www.genome.gov/GWAStudies
Published Genome-Wide Associations through 6/2010
904 published GWA at p<5x10-8 for 165 traits
www.genome.gov/GWAStudies
Lessons from GWAS
• Most (nearly all) previous “candidate” gene association
studies are wrong
• Most common variants have only modest effects on risk
(<< 2 fold OR)
• For most common diseases/traits: identified SNPs only
account for <5-10% of overall risk– NOT USEFUL clinically
• But useful new biology (maybe) ??
– New biologic pathways
– New drug targets
• Other diseases may be different
– AMD
– Thrombosis
– BCL11A and fetal hemoglobin
Lots of tests:
when should we use them?
• Class I: test result will significantly alter
medical management
– Newborn screening (eg. sickle cell, PKU)
– Some cancer predisposition syndromes
(eg. VHL, MEN2, FAP, ?BRCA)
• Class III: test result will have no impact on
medical management
– Huntington Disease, Alzheimer predisposition
• Class II: the grey zone
Venous Thrombosis
GENES
ENVIRONMENT
•Factor V Leiden
• Smoking
• Flying
• Pregnancy
•Elevated FVIII
•Prothrombin 20210
•Protein C/S deficiency
•AT III deficiency
? Others
60%
?
40%
Genetic testing for thrombophilia
• Established risk factors for thrombosis
–
–
–
–
–
–
Factor V Leiden– 5% population frequency (European)
Prothrombin 20210 mutation– 1%
Protein C, Protein S deficiency– each ~1:500
Antithrombin III deficiency– ~1:2500
? Elevated plasma FVIII (or ?FIX, FXI)– 5-10%
Dysfibrinogenemia, others– rare
• Commonly tested factors that DO NOT increase
thrombosis risk
– “Thermolabile” MTHFR (C677T, Ala222Val)– 40% het, 10% homoz
– PAI-1 4G-5G polymorphism– 25% 4G/4G, 50% 4G/5G
Treatment of Venous Thrombosis
Indication
Rx with FVL
Rx without FVL
Acute Thrombosis
Heparin/wararin
Heparin/warfarin
Prophylaxis after
1st event
Warfarin X 3-12 months
Warfarin X 3-12 months
Prophylaxis after
recurrent thrombosis
extended warfarin
(?lifelong)
extended warfarin
(?lifelong)
Pregnancy
?????
Oral contraceptives/
estrogens
?? Relatively contraindicated (? or not)
Other special cases
?????
?????
Testing for Factor V Leiden
(and other thrombophilia mutations)
• Current Indications for testing
• ?????
• Potential future indications:
– Choice and duration of primary therapy for
thrombosis
– Choice and duration of thrombosis prophylaxis:
• During pregnancy
• Postoperatively
• following 1st or subsequent thrombotic event
– Screening before OCP prescription
Lots of tests:
when should we use them?
• Class I: test result will significantly alter
medical management
– Newborn screening (eg. sickle cell, PKU)
– Some cancer predisposition syndromes
(eg. VHL, MEN2, FAP, ?BRCA)
• Class III: test result will have no impact on
medical management
– Huntington Disease, Alzheimer predisposition
• Class II: the grey zone
What do we mean by “personalized medicine”?
• Personalized= tailored, individualized, customized
• Medicine has always been personalized:
– The physician’s charge– the individual patient
• Personalized history, physical exam, laboratory tests
• Personalized diagnosis
• Personalized treatment
– Non “personalized” medicine for the whole community
= public health
•
•
•
•
Vaccination
Safe water and food supply
Waste management
Much larger global impact than “personalized” medicine
What DO we mean by “personalized medicine”?
• Harness the power of genetic information to:
–
–
–
–
–
Improve diagnosis
Tailor treatment to diagnosis
Identify disease susceptibility before illness
Facilitate preventive treatment
Facilitate treatment prescription with minimum toxicity
and maximum efficacy (parmacogenomics)
Gleevec™ – Specifically Targets
An Abnormal Protein, Blocking
Its Ability To Cause Chronic Myeloid Leukemia
Chromosome 9;22
translocation
Bcr-Abl fusion protein
Bcr-Abl fusion protein
Gleevec™
CML
Normal
Pharmacogenomics today
• Pharmacogenomic Biomarkers for 71 drugs (FDA)
http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
• Oncology applications
– Her2/Neu, EGFR, BCR/ABL (efficacy)
– Thiopurine methyltransferase (TPMT)
• 6-MP, azathioprine
– UGT1A1 (irinotecan)
– Dihydropyrimidine dehydrogenase (5-FU)
• Cytochrome P450
– warfarin
– Multiple other drugs:
• antidepressants, tamoxifen, PPIs
• VKORC1
– warfarin
Genetic determinants of Warfarin dose
N Engl J Med 2011;364:1144-53.
Coumadin® Prescribing Information
Pharmacogenomics for warfarin dosing
Sconce et al., Blood 106:2329, 2005
Rieder et al., NEJM 352:2285, 2005
• Clinical value unproven
• Practical limitations:
– VKORC1/CYP2C9 genotype only accounts for ~30% of variance in
warfarin requirement
– Turnaround time
– pill size
Pharmacogenomics today
• Pharmacogenomic Biomarkers for 71 drugs (FDA)
http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
• Oncology applications
– Her2/Neu, EGFR, BCR/ABL (efficacy)
– Thiopurine methyltransferase (TPMT)
• 6-MP, azathioprine
– UGT1A1 (irinotecan)
– Dihydropyrimidine dehydrogenase (5-FU)
• Cytochrome P450
– warfarin
– Multiple other drugs:
• antidepressants, tamoxifen, PPIs
• VKORC1
– warfarin
TMPT variant and chemotherapy toxicity
• TMPT variant alleles (decreased activity)
– 11% heterozygotes
– 0.3% homozygotes
Ann Int Med 2011;154:814.
Conclusion: Insufficient evidence addresses the effectiveness of
TMPT pretesting in patients with chronic inflammatory diseases.
DTC Genetic Testing
•
•
•
•
Mendellian Genetic disorders
pharmacogenomics
Complex (multigenic) disorders
Ancestry
Ng et al., Nature 461:724, 2009.
http://www.gao.gov/new.items/d10847t.pdf
Is there any evidence that DTC Genetic
Testing will improve your health?
Testimonials:
• “It convinced me to go to my doctor who found
my prostate cancer. ____’s DTC genetic testing
saved my life!!”
• “When I found out about my increased risk of
diabetes, I went out and lost 30 pounds!!”
• “When I found out about my increased risk of
lung cancer, I stopped smoking!!”
• …
• …
Is there any evidence that DTC Genetic
Testing will improve your health?
Actual scientific evidence :
• “It convinced me to go to my doctor who found
my prostate cancer. ____’s DTC genetic testing
saved my life!!”
• “When I found out
about my increased risk of
NONE
diabetes, I went out and lost 30 pounds!!”
• “When I found out about my increased risk of
lung cancer, I stopped smoking!!”
• …
• …
Minimally regulated tools available to the
public for predicting/modifying health
• Traditional:
– Astrology
– Tarot cards
– Palm reading
• Modern “scientific”
– “Alternative” medicine ($38 billion/yr)
• Nutraceuticals, homeopathic remedies ($22 billion)
– SNP genotyping
Recreational Genetics
• Ancestry
• Paternity, long lost relatives
New Sequencing Technologies
$0
Sep-11
Mar-11
Sep-10
Mar-10
Sep-09
Mar-09
Sep-08
Mar-08
Sep-07
Mar-07
Sep-06
Mar-06
Sep-05
Mar-05
Sep-04
Mar-04
Sep-03
Mar-03
Sep-02
Mar-02
Sep-01
Cost per Megabase of Raw DNA Sequence
$10,000
$1,000
$100
$10
Moore's Law
Cost per Mb
$1
2000
2010
<1 Human Genome
250-500 Human Genomes
The Future…
• Will be different
– Newborn screening by full genome sequencing
– New/improved therapies
– Complex computational analysis- combinatorial
risk factors
– Much larger data sets– health system wide
– Data to support genotype-specific
therapy/prophylaxis
Additional Source Information
for more information see: http://open.umich.edu/wiki/AttributionPolicy
Slide 18: Ricardipus, flickr,
http://creativecommons.org/licenses/by-sa/2.0/deed.en